ClinicalTrials.gg
CompletedNCT04869592Updated Jan 16, 2026

A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

A Phase 1/2 interventional study of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) and high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in COVID-19, sponsored by National Vaccine and Serum Institute, China. Completed at 1 site in China. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by National Vaccine and Serum Institute, China (part of Sinopharm) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3,100
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.

Enrollment
4th of 18
3,100 · median 714
Started
2021
with 8 others
Phase 1/2
Only one
of the 18
Registered
5th of 18
by date
Lead sponsor
2 of 18
National Vaccine and Serum Institute, China

Among the 18 studies testing CHO cell in COVID-19, this one is the 4th largest by enrollment, is one of 9 that started in 2021, is the only one in phase 1/2, and was the 5th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About CHO cell

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 3 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing CHO cell in COVID-19, or all of them as a file.
02

Study summary

phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older. 300 subjects will be enrolled and divided into 5 age groups: 18-59 years old group, 60-69 years old group, ≥70 years old group, 9-17 years old group and 3-8 years old group. In each group, there are two regimen cohort: low-dose at 0,30, 60 schedule and high-dose at 0,30,60 schedule. The subjects in regimen cohort will be randomized to receive vaccines or placebos at a ratio of 2:1.

Phase II clinical study will explore dose and immunization procedures in 5 age groups, including 18-59 years old group, 60-69 years old group, ≥70 years old group, 9-17 years old group, and 3-8 years old group, with a total of 3280 subjects.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: healthy people aged 3 years and and older who can provide legal identification;
  • The subject and/or his legal guardian and/or his entrusted person can understand the study procedures and , voluntarily sign informed consent form, and be able to comply with the requirements of the clinical study protocol;
  • Inquired about medical history and physical examination, the investigator judged that the health condition is good;
  • No history of SARS-CoV-2 vaccination before enrollment;
  • Females of childbearing age (menarche to menopause) are not pregnant at the time of enrollment (negative urine pregnancy test), not breastfeeding, and have no birth plan within 12 months after enrollment; effective will be taken within 2 weeks before enrollment;
  • During the entire study follow-up period, be able and willing to complete the entire prescribed study plan.

Exclusion criteria

Exclusion Criteria:

First Dose Exclusion Criteria:

  • Confirmed cases of SARS-CoV-2 infection, suspected cases, asymptomatic infections, or close contacts with the above population (check "China Disease Prevention and Control Information System");
  • Axillary body temperature is not less than 37.3℃ (older than 14 years) before vaccination, and axillary body temperature is not less than 37.5℃ (14 years or younger) before vaccination;
  • Positive in SARS-CoV-2 IgG and IgM antibody screening;
  • Have a history of SARS virus infection (self-report, on-site inquiry);
  • Fever (axillary temperature is not less than 37.3℃), dry cough, fatigue, nasal, congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, or dyspnea within 14 days before vaccination;
  • Before vaccination, the results of blood biochemistry, blood routine, urine routine, and coagulation function related indexes are abnormal, which exceed the reference value range, and have clinical significance abnormalities (only refers to phase I);
  • Previous severe allergic reaction to vaccination (such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain);
  • Allergic to any component of the study vaccine (such as aluminum, histidine, etc.);
  • Have a history of convulsions, epilepsy, encephalopathy, long-term alcoholism and drug abuse, thyroidectomy, infectious diseases, mental illness or family history;
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
  • Known or suspected diseases include: severe respiratory disease, severe liver and kidney disease, severe cardiovascular disease, drug-uncontrollable hypertension (systolic blood pressure is not less than 140mmHg, diastolic blood pressure is not less than 90mmHg), high blood glucose, diabetic complications , Malignant tumors, various acute diseases or acute attacks of chronic diseases;
  • Have been diagnosed with congenital or acquired immunodeficiency, infection, lymphoma, leukemia or other diseases;
  • Have a history of abnormal coagulation function (such as coagulation factor deficiency, coagulopathy);
  • Asthenia or splenectomy, functional asthenia caused by any situation;
  • Are receiving anti-TB (tuberculosis) treatment;
  • Have received immune enhancement or inhibitor therapy within 3 months (continuous oral or instillation for more than 14 days);
  • Have received a within 28 days before vaccination, or received other vaccines within 14 days before vaccination;
  • Have received blood products within 3 months before vaccination;
  • Have received other study drugs within 6 months before vaccination;
  • Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
  • Other conditions considered by the investigator to be inappropriate for participation in the study.

Exclusion criteria for the second and third doses of vaccination

  • Positive urine pregnancy test;
  • Have a high fever (axillary temperature is not less than 39.0℃) for three days and severe allergic reaction after the previous dose of vaccination;
  • Severe adverse reactions that are causally related to the previous dose of vaccination;
  • For those newly discovered or newly identified after the previous dose of vaccine that does not meet the first dose selection criteria or meets the first dose exclusion criteria, the investigator will determine whether to continue participating in the study;
  • Other exclusion reasons considered by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,100 participants (actual)

Study arms

  • Experimental
    Phase 1 low-dose group

    Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 1 high-dose group

    Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Placebo comparator
    Phase 1 placebo group

    Biological: placebo

  • Experimental
    Phase 2 low-dose group A

    Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 2 low-dose group B

    Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 2 low-dose group C

    Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 2 low-dose group D

    Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 2 high-dose group A

    Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 2 high-dose group B

    Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 2 high-dose group C

    Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Experimental
    Phase 2 high-dose group D

    Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

  • Placebo comparator
    Phase 2 placebo group A

    Biological: placebo

  • Placebo comparator
    Phase 2 placebo group B

    Biological: placebo

  • Placebo comparator
    Phase 2 placebo group C

    Biological: placebo

  • Placebo comparator
    Phase 2 placebo group D

    Biological: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination

    Phase 1

    Time frame: through 30 minutes after each dose

  2. the incidence of abnormal blood biochemistry, blood routine, blood coagulation function and urine routine on the 4th day after each dose of vaccination

    Phase 1

    Time frame: 4th day each dose

  3. the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination

    Phase 1

    Time frame: through 7 days after each dose

  4. the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination

    Phase 1

    Time frame: through 30 days after each dose

  5. the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination

    Phase 1

    Time frame: through 30 days after each dose

  6. the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination

    Phase 1

    Time frame: up to 12 months after the full course of vaccination

  7. the incidence of AESI from the first dose of vaccination to 12 months after the full course of vaccination

    Phase 1

    Time frame: up to 12 months after the full course of vaccination

  8. Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody(wild Strains) on the 15th day after the full course of vaccination

    Phase 1

    Time frame: 15th day after the full course of vaccination

  9. the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination

    Phase 2

    Time frame: through 30 minutes after each dose

  10. the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination

    Phase 2

    Time frame: through 7 days after each dose

  11. the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination

    Phase 2

    Time frame: through 30 days after each dose

  12. the incidence and severity of non-collective adverse reactions/events within 40 days after each dose of vaccination

    Phase 2

    Time frame: through 40 days after each dose

  13. the incidence and severity of non-collective adverse reactions/events within 60 days after each dose of vaccination

    Phase 2

    Time frame: through 60 days after each dose

  14. the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination

    Phase 2

    Time frame: through 30 days after each dose

  15. the incidence and severity of adverse events leading to withdrawal within 40 days after each dose of vaccination

    Phase 2

    Time frame: through 40 days after each dose

  16. the incidence and severity of adverse events leading to withdrawal within 60 days after each dose of vaccination

    Phase 2

    Time frame: through 60 days after each dose

  17. the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination

    Phase 2

    Time frame: up to 12 months after the full course of vaccination

  18. the incidence of AESI from the the first dose of vaccination to 12 months after the full course of vaccination

    Phase 2

    Time frame: up to 12 months after the full course of vaccination

  19. Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody (wild Strains) on the 15th day after the full course of vaccination

    Phase 2

    Time frame: 15th day after the full course of vaccination

Secondary outcomes

  1. Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Live SARS-CoV-2 neutralization assay) On the 30th day after the full course of vaccination, the neutralizing antibody level (wild Strains)

    Phase 1

    Time frame: 30th day after the full course of vaccination

  2. Seroconversion and Geometric Mean Titer (GMT) of SARS-CoV-2-Specific Binding Antibody (IgG) Before each dose, the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after full course of vaccination

    Phase 1

    Time frame: before each dose , the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

  3. Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Pseudovirus neutralization assay) in the 18-59 years old group before each dose and on the 15th and 30th day after the full course of vaccination

    Phase 1

    Time frame: before each dose,the 15th, 30th day after the full course of vaccination

  4. Geometric Mean Titer (GMT) of SARS-COV-2 specific neutralizing antibody (live SARS-CoV-2 neutralization assay)) On the 30th day after the full course of vaccination

    Phase 2

    Time frame: 30th day after the full course of vaccination

  5. Two-dose group: the neutralizing antibody levels (live SARS-CoV-2 neutralization assay) before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

    Phase 2

    Time frame: before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

  6. Two-dose group: Seroconversion before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

    Phase 2

    Time frame: before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

  7. Two-dose group: Binding Antibody (IgG) before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

    Phase 2

    Time frame: before each dose,the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

  8. Three-dose group: the neutralizing antibody levels (live SARS-CoV-2 neutralization assay) before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

    Phase 2

    Time frame: before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

  9. Three-dose group:Seroconversion before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

    Phase 2

    Time frame: before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

  10. Three-dose group:Binding Antibody (IgG) before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

    Phase 2

    Time frame: before each dose,the 15th day after the second dose, the 15th, 30th, 90th, 180th, 360th day after the full course of vaccination

  11. Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (Pseudovirus neutralization assay) in the 18-59 years old 0,30,60 group before each dose , the 15th and 30th day after the full course of vaccination

    Phase 2

    Time frame: before each dose, 15th, 30th day after the full course of vaccination

07

Study locations

1 site
  • Ning ling Center for Disease Control and Prevention
    Shangqiu, Henan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2023, 28 months.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 28 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2021
First posted
May 3, 2021
StartActual
Apr 25, 2021
Primary completionActual
Aug 29, 2023
CompletionActual
Aug 29, 2023
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04869592
Collaborators
Lanzhou Institute of Biological Products Co., Ltd, Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd., Zhengzhou University
Responsible party
Sponsor
First posted
May 3, 2021
Start date
Apr 25, 2021
Primary completion
Aug 29, 2023
Completion
Aug 29, 2023
Last update
Jan 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion